Skip to main content
Mo-99 Production Facility
Services

ANSTO Nuclear Medicine Project

What is the ANSTO Nuclear Medicine Project?

The ANSTO Nuclear Medicine project includes an export scale Mo-99 Manufacturing Facility and an innovative ANSTO Synroc waste treatment plant. Both of these new facilities will be owned and operated by ANSTO Nuclear Medicine (ANM) Pty Ltd, a majority subsidiary of ANSTO.

The state-of the art Mo-99 Manufacturing Facility is now operational, receiving Molybdenum 99 produced by the adjacent OPAL reactor.  It greatly enhances Mo-99 production capabilities. The ANSTO Synroc waste treatment plant is under construction.

Project timeline

Following completion of construction early in 2019, ANSTO's new Mo-99 Manufacturing Facility entered a 'transition phase', the final operational phase moving from sample production runs to commercial supply.

To commence normal operations, ANSTO required regulatory approval from both ARPANSA on safe operations and health regulator the Therapeutic Goods Authority for product quality.

The regulatory bodies undertook careful review processes before providing approval to ANM Pty Ltd for the supply of Mo-99 in 2019. 

ANM was granted an operational licence by ARPANSA in August 2018, subject to the successful completion of “hot” commissioning and the fulfilment of a number of licence conditions.

In 2019, following an operational incident in the new facility, ARPANSA restricted operations in an amended license to a limited number of production runs.

ANSTO addressed the operational and staffing issues identified by ARPANSA and in March 2020, ARPANSA amended the license to allow a measured increase in production.

2012

The Australian Government committed $168.8 million investment for the ANM project

2013

Siting licence granted from ARPANSA

Approval granted by Department of Sustainability, Environment, Water, Population and Communities

Public Works Committee approval received

2014

 

Licence issued for construction of both the Mo-99 Manufacturing facility and the co-located ANSTO Synroc waste treatment plant

Contract to design and construct the new Mo-99 Manufacturing Facility awarded to Watpac Limited

Construction of Mo-99 Manufacturing Facility commenced

2017

Practical completion of the Mo-99 Manufacturing Facility was achieved late in 2017

2018

 

Cold commissioning successfully completed

Hot commissioning successfully completed

Construction of ANSTO Synroc waste treatment facility commenced

ARPANSA granted an operational license to the Mo-99 Manufacturing Facility late in 2018

2019

Mo-99 Manufacturing Facility moved into the ‘transition phase’ carrying out batch runs of product to support domestic and international customers in their applications to relevant regulatory bodies

Domestic commercial supply commenced in April 2019

Following an operational incident ARPANSA amends license and restricts production runs

2020ARPANSA amends the license to allow a measured increase in production

 

Watch the construction stages of the Mo-99 Manufacturing Facility, part of the ANSTO Nuclear Medicine Project

 

ANM Board of Directors

The ANM Board of Directors provide governance and strategic direction for the project and work effectively with senior management to ensure the delivery of the project. The Board of Directors bring a wealth of knowledge and expertise from within the nuclear science and nuclear medicine industry.

Con Lyras_ANM Project_Board of Directors

Con Lyras, Chair 

Pamela Naidoo_ANM Project_Board of Directors

Pamela Naidoo-Ameglio,
Board Member 

Sheruna Naidoo_ANM Project_Board of Directors

Sheruna Naidoo,
Board Member 

Sarah Pearson_ANM Project_Board of Directors

Sarah Pearson,
Board Member 

Greg Santamaria_ANM Project_Board of Directors

Greg Santamaria,
Board Member 

 

Ask us a question

If you would like to know more about Mo-99 production at ANSTO or the ANSTO Nuclear Medicine Project please contact the ANSTO team.